Literature DB >> 7739245

Long-term results of valve replacement with the St. Jude Medical prosthesis.

E M Baudet1, V Puel, J T McBride, J P Grimaud, F Roques, F Clerc, X Roques, N Laborde.   

Abstract

To assess with truly long follow-up the long-term results of valve replacement with the St. Jude Medical prosthesis (St. Jude Medical, Inc., St. Paul, Minn.), we reviewed the case histories of the first 1112 patients undergoing 1244 valve replacements with this valve between June 12, 1978, and June 12, 1987: 690 male (62%) and 422 female patients, mean age 56 years. A total of 773 patients (69%) had the aortic valve replaced, 207 (19%) the mitral valve, and 132 (12%) the aortic and mitral valves. There were 42 hospital deaths (3.8%). Follow-up was 97.5% complete (8988 patient-years). There were 213 late deaths. Ninety-one (43%) were considered valve-related: sudden death, n = 27; anticoagulant-related hemorrhage, n = 22; thromboembolism, n = 19; prosthetic valve endocarditis, n = 13; valve thrombosis, n = 9; and noninfectious perivalvular leak, n = 1. Overall actuarial survival, including hospital mortality, was 68% +/- 6% (95% confidence limits) 14 years after the operation. Linearized rates of late valve-related events were as follows: thromboembolism, 1.09% per patient-year; anticoagulant-related hemorrhage, 0.94% per patient-year; prosthetic valve endocarditis, 0.32% per patient-year; valve thrombosis, 0.33% per patient-year; and perivalvular leak, 0.19% per patient-year. Actuarial freedom, at 14 years, from thromboembolism was 89% +/- 3%, anticoagulant-related hemorrhage 83% +/- 8%, valve thrombosis 97% +/- 1%, and reoperation 95% +/- 3%. Actuarial freedom from all valve-related deaths and valve-related morbidity and mortality, at 14 years, was 84% +/- 6% and 61% +/- 8%, respectively. We conclude that, because of its low thrombogenicity, low incidence of valve-related events, and low valve-related mortality, the St. Jude Medical valve is one of the best performing mechanical prosthesis currently available. Nevertheless, the late valve-related complications and deaths illustrate that the quest for a "perfect" prosthesis remains unfulfilled.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739245     DOI: 10.1016/S0022-5223(95)70309-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  St. Jude Medical and CarboMedics mechanical heart valves in the aortic position: comparison of long-term results.

Authors:  Ozer Kandemir; Hilmi Tokmakoglu; Ulku Yildiz; Tevfik Tezcaner; A Cem Yorgancioglu; Lihan Gunay; Kaya Suzer; Yaman Zorlutuna
Journal:  Tex Heart Inst J       Date:  2006

2.  Effect of hinge gap width of a St. Jude medical bileaflet mechanical heart valve on blood damage potential--an in vitro micro particle image velocimetry study.

Authors:  Brian H Jun; Neelakantan Saikrishnan; Sivakkumar Arjunon; B Min Yun; Ajit P Yoganathan
Journal:  J Biomech Eng       Date:  2014-09       Impact factor: 2.097

3.  Congenital aortic valve disease. Improved survival and quality of life.

Authors:  R C Elkins; C J Knott-Craig; C McCue; M M Lane
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  St. Jude Medical prosthetic aortic valve malfunction due to pannus formation.

Authors:  Y Naito; M Hachida; T Shimabukuro; M Nonoyama; M Endo; H Koyanagi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-11

5.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08

6.  Mitral valve repair versus replacement in simultaneous aortic and mitral valve surgery.

Authors:  Marian Urban; Jan Pirk; Ondrej Szarszoi; Ivo Skalsky; Jiri Maly; Ivan Netuka
Journal:  Exp Clin Cardiol       Date:  2013

7.  Hemodynamic Performance and Thrombogenic Properties of a Superhydrophobic Bileaflet Mechanical Heart Valve.

Authors:  David L Bark; Hamed Vahabi; Hieu Bui; Sanli Movafaghi; Brandon Moore; Arun K Kota; Ketul Popat; Lakshmi P Dasi
Journal:  Ann Biomed Eng       Date:  2016-04-20       Impact factor: 3.934

8.  Hemocompatibility and Hemodynamics of Novel Hyaluronan-Polyethylene Materials for Flexible Heart Valve Leaflets.

Authors:  David A Prawel; Harold Dean; Marcio Forleo; Nicole Lewis; Justin Gangwish; Ketul C Popat; Lakshmi Prasad Dasi; Susan P James
Journal:  Cardiovasc Eng Technol       Date:  2014-03-01       Impact factor: 2.495

9.  Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation.

Authors:  J P A Puvimanasinghe; J J M Takkenberg; M B Edwards; M J C Eijkemans; E W Steyerberg; L A Van Herwerden; K M Taylor; G L Grunkemeier; J D F Habbema; A J J C Bogers
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

Review 10.  Use of anticoagulants in elderly patients: practical recommendations.

Authors:  Helia Robert-Ebadi; Grégoire Le Gal; Marc Righini
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.